Pricing

Kaleido Biosciences Inc (KLDO)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Daniel L. Menichella
Employees:
80
18 CROSBY DRIVE, BEDFORD, MA, 01730
617-674-9000

Are you looking for this stock instead?

Kaleido Biosciences, Inc. develops microbiome metabolic therapies. Company develops KB195 for the treatment of patients with urea cycle disorder. KB295 to treat ulcerative colitis; KB174 to treat hepatic encephalopathy; KB109 to treat COVID-19 disease.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available